ES2593859T3 - Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos - Google Patents

Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos Download PDF

Info

Publication number
ES2593859T3
ES2593859T3 ES09807798.5T ES09807798T ES2593859T3 ES 2593859 T3 ES2593859 T3 ES 2593859T3 ES 09807798 T ES09807798 T ES 09807798T ES 2593859 T3 ES2593859 T3 ES 2593859T3
Authority
ES
Spain
Prior art keywords
branched
linear
saturated
optionally substituted
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09807798.5T
Other languages
English (en)
Spanish (es)
Inventor
Marianne D. Sadar
Nasrin R. Mawji
Jun Wang
Raymond J. Andersen
David E. Williams
Mike Leblanc
Lu-Ping Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
British Columbia Cancer Agency BCCA
Original Assignee
University of British Columbia
British Columbia Cancer Agency BCCA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41706796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2593859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of British Columbia, British Columbia Cancer Agency BCCA filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2593859T3 publication Critical patent/ES2593859T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES09807798.5T 2008-08-22 2009-08-24 Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos Active ES2593859T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13627708P 2008-08-22 2008-08-22
US136277P 2008-08-22
PCT/CA2009/001173 WO2010020055A1 (en) 2008-08-22 2009-08-24 Small molecule inhibitors of n-terminus activation of the androgen receptor

Publications (1)

Publication Number Publication Date
ES2593859T3 true ES2593859T3 (es) 2016-12-13

Family

ID=41706796

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09807798.5T Active ES2593859T3 (es) 2008-08-22 2009-08-24 Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos

Country Status (13)

Country Link
US (2) US9487479B2 (https=)
EP (1) EP2331501B1 (https=)
JP (1) JP2012500778A (https=)
CN (1) CN102131775B (https=)
AU (1) AU2009284668B2 (https=)
BR (1) BRPI0917818A2 (https=)
CA (1) CA2728103C (https=)
CL (1) CL2011000341A1 (https=)
CO (1) CO6351779A2 (https=)
ES (1) ES2593859T3 (https=)
MX (1) MX339300B (https=)
RU (1) RU2519948C2 (https=)
WO (1) WO2010020055A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131775B (zh) 2008-08-22 2015-12-16 不列颠哥伦比亚癌症局分支机构 雄激素受体n-末端活化的小分子抑制剂
AU2015266654A1 (en) * 2014-05-30 2016-12-01 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10799416B2 (en) * 2017-01-11 2020-10-13 Jonathan Taves Self-treating upper neck system for therapeutic mobilization
CN107468690B (zh) 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh) 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
RU2694259C2 (ru) * 2017-10-16 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2700573C2 (ru) * 2017-10-16 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2696287C2 (ru) * 2017-10-16 2019-08-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2694373C2 (ru) * 2017-10-16 2019-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0317057A (ja) * 1989-06-15 1991-01-25 Fujisawa Pharmaceut Co Ltd 新規５員環複素環化合物
CA2302169A1 (en) 1998-06-30 2000-01-13 The University Of British Columbia Inhibitors of androgen-independent activation of androgen receptor
BR0110745A (pt) * 2000-05-09 2003-12-30 Adpharma Inc Compostos de piperazinadiona
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
CN102131775B (zh) 2008-08-22 2015-12-16 不列颠哥伦比亚癌症局分支机构 雄激素受体n-末端活化的小分子抑制剂
AU2015266654A1 (en) 2014-05-30 2016-12-01 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use

Also Published As

Publication number Publication date
US9487479B2 (en) 2016-11-08
AU2009284668A1 (en) 2010-02-25
US20170239216A1 (en) 2017-08-24
HK1153198A1 (zh) 2012-03-23
JP2012500778A (ja) 2012-01-12
MX2011001890A (es) 2011-06-20
AU2009284668B2 (en) 2015-07-09
CL2011000341A1 (es) 2011-09-02
CO6351779A2 (es) 2011-12-20
CA2728103A1 (en) 2010-02-25
MX339300B (es) 2016-05-19
EP2331501A1 (en) 2011-06-15
EP2331501B1 (en) 2016-07-20
BRPI0917818A2 (pt) 2017-02-21
US20110230539A1 (en) 2011-09-22
RU2519948C2 (ru) 2014-06-20
RU2011110743A (ru) 2012-09-27
CA2728103C (en) 2017-06-27
EP2331501A4 (en) 2012-06-06
WO2010020055A1 (en) 2010-02-25
CN102131775B (zh) 2015-12-16
CN102131775A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
ES2593859T3 (es) Moléculas pequeñas inhibidoras de la activación del extremo N del receptor de andrógenos
AR028985A1 (es) Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene
Feula et al. Synthesis of azetidines and pyrrolidines via iodocyclisation of homoallyl amines and exploration of activity in a zebrafish embryo assay
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
Chen et al. Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model
AR071548A1 (es) Amidas de acido 3-substituido-4-oxo-3, 4-dihidro-imidazo[5, 1-d]1, 2, 3, 5-tetracina-8-carboxilico, un metodo para su preparacion e intermediarios de su sintesis, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de diversos tipos de cancer
DOP2001000270A (es) Agonistas del receptor 3-adrenergico y usos de los mismos
UY28968A1 (es) (orto-fenil)-anilidas de ácido 1-metil-3-trifluorometil-pirazol-4-carboxílico y su uso como fungicida
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
AR044177A1 (es) Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona
CO4650038A1 (es) Derivados del indazol sustituidos y compuestos relacionados
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado
AR071780A1 (es) Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
EA200501888A1 (ru) Замещённые пиразолопиримидины, способ их получения и их применение для борьбы с патогенными грибами, а также содержащие их средства
PA8660601A1 (es) Pirazolopiridinas y sales de las mismas, una composicion farmaceutica que comprende dichos compuestos, un metodo para prepararlos y su uso
JPWO2011118812A1 (ja) 神経変性疾患治療薬
Liao et al. Synthesis, photophysical properties and biological evaluation of β-alkylaminoporphyrin for photodynamic therapy
UY27324A1 (es) Nuevas sales de napsilato i